摘要
目的:探讨恶性脑胶质瘤手术后应用单药替莫唑胺(TMZ)方案化疗与尼莫司汀联合顺铂(ACNU+DDP)化疗的效果。方法:选取经病理证实为恶性脑胶质瘤患者60例,手术治疗后随机分为TMZ和ACNU+DDP两组,按标准方案分别给予4～6个疗程的化疗。每个化疗期间分别复查头颅MRI及肝肾功、血细胞分析,并与化疗前资料相比较,判断病情变化。结果:TMZ组有效率达为44.0%,ACNU+DDP组为14.28%,两组相差显著(P<0.05)。TMZ组严重副反应发生率为16.0%,ACNU+DDP组为31.43%,两组相差显著(P<0.05)。结论:TMZ比ACNU+DDP不仅能更好的改善恶性胶质瘤患者的预后,提高其生活质量,而且具有较高的安全性。
Objective：To determine the efficacy of tmozolomide（TMZ）vs Nimustine（ACNU）and Cisplatin（DDP） in the patients with malignant gliomas.Methods：Sixty patients with malignant gliomas undergoing the surgery were randomly divided into two groups,i.e.TMZ treatment and ACNU treatment group,where the patients were treated respectively by TMZ and ACNU according to the Stan-dard program.The clinical following-up and contrast GD-MRI,Kidney function,Blood cell analysis examination were performed to evaluate the tumor progression.The data of the following-up and imagings after the chemotherapy were compared to those before the chemotherapy.Results：The image-based response rates in TMZ and ACNU groups were 44.0% and 14.28% respectively.Otherwise Side effects rates in TMZ and ACNU groups were 16.0% and 31.43% respectively.There was significant difference between TMZ and ACNU groups（P〈0.05）.Conclusion：TMZ can improve the patients with malignant gliomas in the symptoms and survival quality better,and produce higher response rate compared to ACNU and DDP in the patients with malignant gliomas after the surgery.
出处
《现代生物医学进展》
CAS
2010年第21期4094-4096,共3页
Progress in Modern Biomedicine
关键词
恶性脑胶质瘤
替莫唑胺
尼莫司汀
顺铂
Temozolomide （TMZ）
Nimustine（ACNU）
Cisplatin（DDP） Malignant glioma
